[1] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000.
|
[2] |
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell⁃mediated effector immunity[J]. J Allergy Clin Immunol, 2015,135(3):626⁃635. doi: 10.1016/j.jaci. 2014.11.001.
|
[3] |
Cavani A, Pennino D, Eyerich K. Th17 and Th22 in skin allergy[J]. Chem Immunol Allergy, 2012,96:39⁃44. doi: 10.1159/000 331870.
|
[4] |
Jiao Q, Qian Q, Liu C, et al. T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T⁃cell costimulator[J]. Br J Dermatol, 2020,182(3):648⁃657. doi: 10.1111/bjd.18040.
|
[5] |
Leyva⁃Castillo JM, Yoon J, Geha RS. IL⁃22 promotes allergic airway inflammation in epicutaneously sensitized mice[J]. J Allergy Clin Immunol, 2019,143(2):619⁃630.e7. doi: 10.1016/j.jaci.2018.05.032.
|
[6] |
Taube C, Tertilt C, Gyülveszi G, et al. IL⁃22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease[J/OL]. PLoS One, 2011,6(7):e21799[2020⁃10⁃15]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone. 0021799. doi: 10.1371/journal.pone.0021799.
|
[7] |
Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs[J]. Allergy, 2020,75(7):1582⁃1605. doi: 10.1111/all.14318.
|
[8] |
Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food allergy[J]. Allergol Int, 2020,69(2):204⁃214. doi: 10.1016/j.alit.2019.08.013.
|
[9] |
Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch[J]. Cell, 2017,171(1):217⁃228.e13. doi: 10.1016/j.cell.2017.08.006.
|
[10] |
Ko E, Chehade M. Biological therapies for eosinophilic esophagitis: where do we stand?[J]. Clin Rev Allergy Immunol, 2018,55(2):205⁃216. doi: 10.1007/s12016⁃018⁃8674⁃3.
|
[11] |
Kim BE, Leung D. Significance of skin barrier dysfunction in atopic dermatitis[J]. Allergy Asthma Immunol Res, 2018,10(3):207⁃215. doi: 10.4168/aair.2018.10.3.207.
|
[12] |
Man MQ, Hatano Y, Lee SH, et al. Characterization of a hapten⁃induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges[J]. J Invest Dermatol, 2008,128(1):79⁃86. doi: 10.1038/sj.jid.5701 011.
|
[13] |
Elias PM, Wakefield JS. Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2014,134(4):781⁃791.e1. doi: 10.1016/j.jaci.2014.05.048.
|
[14] |
Berdyshev E, Goleva E, Bronova I, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines[J/OL]. JCI Insight, 2018,3(4)[2020⁃10⁃15]. https://insight.jci.org/articles/view/98006. doi: 10.1172/jci.insight.98006.
|
[15] |
Brauweiler AM, Goleva E, Leung D. Interferon⁃γ protects from staphylococcal alpha toxin⁃induced keratinocyte death through apolipoprotein L1[J]. J Invest Dermatol, 2016,136(3):658⁃664. doi: 10.1016/j.jid.2015.12.006.
|
[16] |
Howell MD, Gallo RL, Boguniewicz M, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus[J]. Immunity, 2006,24(3):341⁃348. doi: 10.1016/j.immuni.2006.02.006.
|
[17] |
Wilson SR, Thé L, Batia LM, et al. The epithelial cell⁃derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J]. Cell, 2013,155(2):285⁃295. doi: 10.1016/j.cell.2013.08.057.
|
[18] |
Andersen HH, Elberling J, Sølvsten H, et al. Nonhistaminergic and mechanical itch sensitization in atopic dermatitis[J]. Pain, 2017,158(9):1780⁃1791. doi: 10.1097/j.pain.0000000000000980.
|
[19] |
Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease[J]. Nat Rev Drug Discov, 2009,8(8):645⁃660. doi: 10.1038/nrd2653.
|
[20] |
Noval Rivas M, Burton OT, Wise P, et al. Regulatory T cell reprogramming toward a Th2⁃cell⁃like lineage impairs oral tolerance and promotes food allergy[J]. Immunity, 2015,42(3):512⁃523. doi: 10.1016/j.immuni.2015.02.004.
|
[21] |
Massoud AH, Charbonnier LM, Lopez D, et al. An asthma⁃associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17⁃like cells[J]. Nat Med, 2016,22(9):1013⁃1022. doi: 10.1038/nm.4147.
|
[22] |
Durham AL, Caramori G, Chung KF, et al. Targeted anti⁃inflammatory therapeutics in asthma and chronic obstructive lung disease[J]. Transl Res, 2016,167(1):192⁃203. doi: 10. 1016/j.trsl.2015.08.004.
|
[23] |
中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019,54(2):81⁃100. doi: 10.3760/cma.j.issn.1673⁃0860.2019.02.001.
|
[24] |
Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS[J]. J Am Acad Dermatol, 2020,82(6):1328⁃1336. doi: 10.1016/j.jaad.2020.02.060.
|
[25] |
Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti⁃IL⁃13 monoclonal antibody) in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo⁃controlled phase II trial (TREBLE)[J]. J Am Acad Dermatol, 2018,78(5):863⁃871.e11. doi: 10.1016/j.jaad.2018.01.017.
|
[26] |
Wollenberg A, Howell MD, Guttman⁃Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti⁃IL⁃13 mAb[J]. J Allergy Clin Immunol, 2019,143(1):135⁃141. doi: 10.1016/j.jaci.2018.05.029.
|
[27] |
Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate⁃to⁃severe atopic dermatitis: randomized, phase II, long⁃term extension study[J]. J Allergy Clin Immunol, 2018,142(4):1121⁃1130.e7. doi: 10.1016/j.jaci.2018.03.018.
|
[28] |
Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial[J]. JAMA Pediatr, 2019,174(1):29⁃37. doi: 10.1001/jamapediatrics.2019.4476.
|